AI helps medicinal chemists prioritize the most promising compounds before synthesis, allowing teams to focus experimental resources on the designs most likely to succeed. This AI-guided approach improves decision-making throughout discovery while reducing unnecessary experimental work.
By combining medicinal chemistry expertise with predictive models continuously refined using experimental data, IDD improves molecule design and supports faster, more informed discovery decisions.
Predictive models trained on an initial chemical series helped guide a successful second series in an inflammation program.
In selected data-rich discovery programs, AI helped scientists focus on the most promising compounds while reducing unnecessary synthesis.
Turning data into confident design decisions that help scientists discover better medicines.